Registration Process of Generic Budesonide DPI as per USFDA Guidelines
Dossier Submission of Budesonide Dry Powder Inhaler with the application of eCTD Software
(Sprache: Englisch)
The purpose of this book is to develop a hypothetical dossier based on regulations and guidances which are required to be followed when an actual submission is filed to the USFDA, with an objective to meet the Common Technical Document(CTD) requirements....
Leider schon ausverkauft
versandkostenfrei
Buch
61.90 €
Produktdetails
Produktinformationen zu „Registration Process of Generic Budesonide DPI as per USFDA Guidelines “
Klappentext zu „Registration Process of Generic Budesonide DPI as per USFDA Guidelines “
The purpose of this book is to develop a hypothetical dossier based on regulations and guidances which are required to be followed when an actual submission is filed to the USFDA, with an objective to meet the Common Technical Document(CTD) requirements. For this purpose, Budesonide Dry Powder Inhaler(DPI) is selected as a product to prepare a hypothetical dossier. In terms of volume by 2026 it is expected that requirement of DPI in USA would be increased and may reach up to 400 million units per year due to increasing air pollution and increased rate of respiratory diseases in children as well as old age people. In this study an ANDA has been prepared which includes data of the different modules such as Module 1: Administrative Information, Module 2: Quality Overall Summary, Module 3: Quality (Drug substance and Drug product) and Module 5: Clinical Study Reports. To get the ANDA approval, generic applicants has to show scientific evidence that their product is bioequivalent to the innovators drug product. Once the application is submitted it will undergo through a thorough review process by CDER, OGD & OCP and if they find it satisfactory, product will get approval from FDA.
Autoren-Porträt von Hansal Gandhi
Gandhi, HansalHansal Gandhi is dedicated, detail oriented and goal driven professional with broad proficiencies in Regulatory Affairs. He has completed his Masters of Pharmacy in the field of Pharmaceutical Regulatory Affairs and has very rich experience in the field of Drug Regulatory Submissions & eCTD submissions of Drugs, Biologics & Medical Devices.
Bibliographische Angaben
- Autor: Hansal Gandhi
- 2019, 136 Seiten, Maße: 22 cm, Kartoniert (TB), Englisch
- Verlag: LAP Lambert Academic Publishing
- ISBN-10: 6200080941
- ISBN-13: 9786200080943
Sprache:
Englisch
Kommentar zu "Registration Process of Generic Budesonide DPI as per USFDA Guidelines"
0 Gebrauchte Artikel zu „Registration Process of Generic Budesonide DPI as per USFDA Guidelines“
Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
---|
Schreiben Sie einen Kommentar zu "Registration Process of Generic Budesonide DPI as per USFDA Guidelines".
Kommentar verfassen